Pfizer to Present 45 Oncology Abstracts at ESMO 2026
NEW YORK — September 28, 2026 Pfizer Inc. announced that it will present data from 45 company-sponsored, investigator-sponsored and...
melanoma
Advertisement
Medicus Pharma Advances Precision Oncology Strategy With CD228V
PHILADELPHIA, Pennsylvania — September 8, 2026 Medicus Pharma Ltd. announced a strategic transformation into a precision oncology-led biotechnology company,...
NTx Bio Advances Personalized Cancer Vaccine Manufacturing
Rio Rancho, New Mexico, August 19, 2026 NTx Bio is advancing the manufacturing infrastructure supporting personalized cancer vaccines through...
Merck and Moderna Report Phase 3 Melanoma Success
Rahway, New Jersey, and Cambridge, Massachusetts, August 19, 2026 Merck and Moderna announced positive topline results from the Phase...
Medicenna Advances MDNA11 and Bizaxofusp Clinical Programs
TORONTO and HOUSTON, August 14, 2026 Medicenna Therapeutics Corp. reported its first-quarter fiscal 2027 financial results and provided a...
Advertisements
Eikon Therapeutics Selects EIK1001 Dose for Phase 2/3 Melanoma Trial
MILLBRAE, Calif., August 11, 2026 Eikon Therapeutics announced the selection of a 0.60 mg/m² dose of EIK1001 for patients...
MacroGenics Reports Positive Phase 1 MGC026 Cancer Study Update
ROCKVILLE, MD, July 23, 2026 MacroGenics, Inc. announced a significant clinical update from its ongoing Phase 1 study of...
Evaxion Highlights Phase 2 EVX-01 Melanoma Results
Copenhagen, Denmark, July 17, 2026 Evaxion A/S announced that it will present three-year clinical efficacy data from its Phase...
Castle Biosciences Reports DecisionDx-Melanoma Improves SLNB Risk Prediction
FRIENDSWOOD, Texas, June 25, 2026 Castle Biosciences announced the publication of a prospective multicenter study in Dermatology and Therapy...
Regeneron Pharmaceuticals Melanoma Trial Misses Primary PFS Goal
TARRYTOWN, New York, May 15, 2026 Regeneron Pharmaceuticals announced updated results from its Phase 3 melanoma trial evaluating the...
Advertisement
